| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Allergy and Immunology, National Research Institute for Child Health and Development, Tokyo, Japan;
Chiba Municipal Kaihin Hospital, Chiba, Japan;
Hachiouji Metropolitan Children’s Hospital, Tokyo, Japan; and
Graduate School of Medicine, Chiba University, Chiba, Japan
Kawasaki disease (KD) is an acute vasculitis of infants and young children, preferentially affecting the coronary arteries. Intravenous infusion of high dose Ig (IVIG) effectively reduces systemic inflammation and prevents coronary artery lesions in KD. To investigate the mechanisms underlying the therapeutic effects of IVIG, we examined gene expression profiles of PBMC and purified monocytes obtained from acute patients before and after IVIG therapy. The results suggest that IVIG suppresses activated monocytes and macrophages by altering various functional aspects of the genes of KD patients. Among the 18 commonly decreased transcripts in both PBMC and purified monocytes, we selected six genes, FCGR1A, FCGR3A, CCR2, ADM, S100A9, and S100A12, and confirmed the microarray results by real-time RT-PCR. Moreover, the expressions of Fc
RI and FcRIII on monocytes were reduced after IVIG. Plasma S100A8/A9 heterocomplex, but not S100A9, levels were elevated in patients with acute KD compared with those in febrile controls. Furthermore, S100A8/A9 was rapidly down-regulated in response to IVIG therapy. Persistent elevation of S100A8/A9 after IVIG was found in patients who later developed coronary aneurysms. These results indicate that the effects of IVIG in KD may be mediated by suppression of an array of immune activation genes in monocytes, including those activating FcRs and the S100A8/A9 heterocomplex.
This article has been cited by other articles:
|
|
 |
|
  S. V. Kaveri, S. Lacroix-Desmazes, and J. Bayry The Antiinflammatory IgG N. Engl. J. Med., July 17, 2008; 359(3): 307 - 309. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Viemann, K. Barczyk, T. Vogl, U. Fischer, C. Sunderkotter, K. Schulze-Osthoff, and J. Roth MRP8/MRP14 impairs endothelial integrity and induces a caspase-dependent and -independent cell death program Blood, March 15, 2007; 109(6): 2453 - 2460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Foell, H. Wittkowski, T. Vogl, and J. Roth S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules J. Leukoc. Biol., January 1, 2007; 81(1): 28 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Burns S100 Proteins in the Pathogenesis of Kawasaki Disease J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1265 - 1267. [Full Text] [PDF]
|
|
|
|
|
|
K. Hirono, D. Foell, Y. Xing, S. Miyagawa-Tomita, F. Ye, M. Ahlmann, T. Vogl, T. Futatani, C. Rui, X. Yu, et al. Expression of Myeloid-Related Protein-8 and -14 in Patients With Acute Kawasaki Disease J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1257 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Vo, V. Cam, M. Toyoda, D. P. Puliyanda, M. Lukovsky, S. Bunnapradist, A. Peng, K. Yang, and S. C. Jordan Safety and Adverse Events Profiles of Intravenous Gammaglobulin Products Used for Immunomodulation: A Single-Center Experience Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 844 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Jordan and M. D. Pescovitz Presensitization: The Problem and Its Management Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 421 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Foell, J. Roth, J. Abe, H. Saito, and M. Terai S100 Proteins in Monitoring Inflammation: The Importance of a Gold Standard and a Validated Methodology J. Immunol., September 15, 2005; 175(6): 3459 - 3460. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
